At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Not Yet Opened 07-07 16:08:40
11.530
-0.260
-2.21%
High12.090Low11.250Vol4.04M
Open12.000D1 Closing11.790Amplitude7.12%
Mkt Cap12.23BTradable Cap12.23BTotal Shares1.06B
T/O47.04MT/O Rate0.38%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Race to Launch Weight-loss Pills Heats up as Smaller Players Advance
Reuters  ·  00:12
Race to Launch Weight-loss Pills Heats up as Smaller Players Advance
Ascletis Pharma Completes HKD 1.15 Million Buyback; Uncancelled Repurchased Shares Reach 9.63 Million
Bulletin Express  ·  07-07 17:25
Ascletis Pharma Completes HKD 1.15 Million Buyback; Uncancelled Repurchased Shares Reach 9.63 Million
ASCLETIS-B Executes Share Buyback on July 7, Spending HK$1.153 Million
Stock News  ·  07-07 17:20
ASCLETIS-B Executes Share Buyback on July 7, Spending HK$1.153 Million
Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation
Reuters  ·  07-07 17:12
Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation
Ascletis Pharma Submits Two Obesity Drug Applications to US FDA
MT Newswires Live  ·  07-06 15:40
Ascletis Pharma Submits Two Obesity Drug Applications to US FDA
Ascletis Pharma to Use up to Hk$300 Million for Share Repurchase
Reuters  ·  07-06 15:15
Ascletis Pharma to Use up to Hk$300 Million for Share Repurchase
Ascletis Hits 5-week High on New Drug Applications for Obesity Treatment
Reuters  ·  07-06 13:34
Ascletis Hits 5-week High on New Drug Applications for Obesity Treatment
Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?
Simply Wall St.  ·  07-06 13:22
Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?
ASCLETIS-B Submits Two IND Applications to US FDA for Obesity Treatments: Monthly Peptide Amylin Receptor Agonist ASC36 and ASC36_35 Combination Monthly Injection
Stock News  ·  07-06 08:10
ASCLETIS-B Submits Two IND Applications to US FDA for Obesity Treatments: Monthly Peptide Amylin Receptor Agonist ASC36 and ASC36_35 Combination Monthly Injection
Ascletis Submits Two Obesity-drug IND Applications to US FDA for Asc36, Asc36_35 FDC Injections
Reuters  ·  07-06 08:00
Ascletis Submits Two Obesity-drug IND Applications to US FDA for Asc36, Asc36_35 FDC Injections
Ascletis Pharma - Submits Two Ind Applications to U.S. FDA for Obesity Treatment
THOMSON REUTERS  ·  07-06 08:00
Ascletis Pharma - Submits Two Ind Applications to U.S. FDA for Obesity Treatment
Ascletis Pharma Maintains Stable Share Capital Structure in June 2026; Public Float Above 25% Threshold
Bulletin Express  ·  07-03
Ascletis Pharma Maintains Stable Share Capital Structure in June 2026; Public Float Above 25% Threshold
Ascletis Pharma Discloses 145,000-Share Buyback on 30 June; Outstanding Shares Steady at 1.06 Billion
Bulletin Express  ·  06-30
Ascletis Pharma Discloses 145,000-Share Buyback on 30 June; Outstanding Shares Steady at 1.06 Billion
Ascletis Pharma Announces Up to HK$300 Million Share Buyback, Covering 10% of Issued Stock
Bulletin Express  ·  06-30
Ascletis Pharma Announces Up to HK$300 Million Share Buyback, Covering 10% of Issued Stock
Ascletis Pharma - to Use up to Hk$300 Mln for Share Repurchase
THOMSON REUTERS  ·  06-30
Ascletis Pharma - to Use up to Hk$300 Mln for Share Repurchase
Ascletis Pharma Plans up to Hk$300 Million Share Buyback Under Mandate
Reuters  ·  06-30
Ascletis Pharma Plans up to Hk$300 Million Share Buyback Under Mandate
Ascletis Revises Articles: Sets US$700,000 Authorised Capital, Enables Virtual Meetings and Three-Year Director Rotation
Bulletin Express  ·  06-29
Ascletis Revises Articles: Sets US$700,000 Authorised Capital, Enables Virtual Meetings and Three-Year Director Rotation
Ascletis Pharma Holds Annual Shareholder Meeting
Reuters  ·  06-29
Ascletis Pharma Holds Annual Shareholder Meeting
Ascletis Pharma Shareholders Approve Amended and Restated Bylaws
Reuters  ·  06-29
Ascletis Pharma Shareholders Approve Amended and Restated Bylaws
ASCLETIS-B Shares Surge Over 7% on FDA IND Approval for ASC35 Phase I Study and GIC's Consistent Share Purchases
Stock News  ·  06-29
ASCLETIS-B Shares Surge Over 7% on FDA IND Approval for ASC35 Phase I Study and GIC's Consistent Share Purchases

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--